4sc
Manufacturing · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Fraunhoferstr. Planegg 22, Krailling, Ba...Phone Number
+49 897007630Website
www.4sc.deRevenue
$17.4 MillionStock Symbol
VSCIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About 4sc
4SC AG focuses on the development of effective medications for cancer patients, aiming to provide treatments that are more tolerable and effective than existing therapies, ultimately enhancing the quality of life for patients. The company currently has no products in development or operational activities. Additionally, there are no ongoing or planned clinical studies at this time. 4SC AG is involved in partnerships and collaborations, but recent news indicates significant changes in its capital structure.Explore more
4sc Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is 4sc your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on 4sc recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at 4sc
4sc, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when 4sc launches new products
Funding: Get notified immidiatlly once 4sc has new funding data
Check if 4sc has recently received funding, and reach out quickly before it becomes old news!
Check out if 4sc is spiking on competitors!
Click to see if 4sc had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
4sc is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
4sc is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about 4sc.
4sc Tech Stack
A closer look at the technologies used by 4sc
See more technologies
4sc News & Media
The 4SC (ETR:VSC) Share Price Is Down 55% So Some Shareholders Are Wishing They Sold
We think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly...Dynavax’s SD-101 and 4SC’s Domatinostat Demonstrate Synergy and Induce a Systemic Anti-tumor Response in Preclinical Models
BERKELEY, Calif. and PLANEGG-MARTINSRIED, Germany, April 01, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) and 4SC AG (FSE Prime Standard: VSC) today announced the combination of 4SC’s orally available class I selective HDAC inhibitor domatinostat (4SC-202) with Dynavax’s intratumoral TLR9 agonist SD-101 induced a systemic anti-tumoral immune response in tumor mouse models, resulting in the significant decrease in tumor size of both target tumors and distant site metasInthera Bioscience Raises €4.7M Second Tranche of €9.6M Series A
Inthera Bioscience AG, a Wädenswil, Switzerland-based pre-clinical stage oncology company targeting the inhibition of protein-protein interactions with innovative small molecule chemistry, secured the second €4.7m tranche of its Series A financing, bringing the total amount to €9.6m. Backers included M Ventures, Aglaia BioMedical Ventures, and Novo Seeds. The company also announced that three senior Pharma […] The post Inthera Bioscience Raises €4.7M Second Tranche of €9.6M Series A appeared fir
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding 4sc
Sign Up For FreeTo access detailed company insights
4SC AG focuses on the development of effective medications for cancer patients, aiming to provide treatments that are more tolerable and effective than existing therapies, ultimately enhancing the quality of life for patients. The company currently has no products in development or operational activities. Additionally, there are no ongoing or plann... Read More
